期刊文献+

外科病区注射用兰索拉唑合理用药调查分析 被引量:5

Investigation and Analysis of Rational Using Lansoprazole for Injection in the Surgical Ward
下载PDF
导出
摘要 目的促进医院注射用兰索拉唑的合理应用。方法制订质子泵抑制剂用药评价标准,组织抽查小组,对2012年2月外科病区病历进行抽查,对注射用兰索拉唑的适应证、用法用量等进行合理性分析。结果共抽查100份病例,存在不合理用药病例49例,合格率为51.00%。存在问题有使用无明确指征和用药疗程过长等。结论外科住院患者注射用质子泵抑制剂存在不合理用药情况,医院应加快制订质子泵抑制剂使用标准或规范,以提高医院注射用质子泵抑制剂使用的合理性。 Objective To analyze the situation of rational use of drugs which is ]ansoprazole for injection in surgical wards. Methods develop evaluation standard for proton pump inhibitor drug use, organize examination group, and examine the cases in surgical wards randomly on lansoprazole needle indications,usage and dosage analysis of rationality on Feb. 2012. Results A total sample of 100 cases, 49 cases are irrational drug use,the qualified rate is 51.00%. The problem is to use without a clear indication and treatment period is too long. Conclusion It exists that irrational use of proton pump iuhibitors on surgical inpatients,hospital should speed up the development of proton pump inhibitors using standard or specification,in order to improve the rationality of proton pump inhibitor use in hospital.
出处 《中国药业》 CAS 2013年第3期26-27,共2页 China Pharmaceuticals
关键词 质子泵抑制剂 注射用兰索拉唑 合理用药 proton pump inhibitors lansoprazole injection rational drug use
  • 相关文献

参考文献5

二级参考文献16

  • 1郑伟华,叶云婕,黄禹,何蕙泾.质子泵抑制剂与H_2受体拮抗剂在化疗中的临床应用比较[J].广东医学,2004,25(9):1092-1094. 被引量:13
  • 2Spirt MJ. Stress-related mucosal disease: risk factors and prophylactic therapy[J]. Clin Ther, 2004, 26(2): 197-213.
  • 3Lev R, Molot MD, McNamara J, et al. "Stress" ulcers following war wounds in Vietnam. A morphologic and histochemical study [J]. Lab Invest, 1971, 25(6) : 491-502.
  • 4Cook DJ, Fuller HD, Guyan GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group[J]. N Engl J Med, 1994, 330(6):377-381.
  • 5Allen ME, Kopp B J, Erstad BL. Stress ulcer prophylaxis in the postoperative period [J].Am J Health Syst Pharm, 2004, 61(6): 588-596.
  • 6ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP commission on therapeutics and approved by the ASHP board of directors on november 14, 1998 [J]. Am J Health Syst Pharm, 1999, 56(4): 347-379.
  • 7Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units [J]. Am J Health Syst Pharm, 2007,64(13): 1396-1400.
  • 8Lau JY, Sung J J, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers[J]. N Engl J Med, 2000, 343: 310-316.
  • 9Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding[J]. N Engl J Med,2007, 356(16): 1631-1640.
  • 10Barkun A, Bardou M, Marshall JK. Nonvariceal upper GI bleeding consensus conference group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding[ J ]. Ann Intern Med, 2003, 139(10): 843-857.

共引文献331

同被引文献28

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部